Current management of mantle cell lymphoma

Drugs

Volumn 67, Issue 12, 2007, Pages 1689-1702

  Weigert, Oliver ^a   Unterhalt, Michael ^a   Hiddemann, Wolfgang ^a   Dreyling, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BH3 PROTEIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; I KAPPA B; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN P21; PROTEIN P53; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; CYTOGENETICS; DRUG MEGADOSE; DRUG STRUCTURE; FATIGUE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; INJECTION SITE REACTION; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NONHODGKIN LYMPHOMA; PATHOGENESIS; PROGNOSIS; RADIOIMMUNOTHERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, MANTLE-CELL; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION;

EID: 34547928768     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767120-00004     Document Type: Review

References (100)

1. Jaffe ES, Harris NL, Stein H. Tumours of the haemopoitic and lymphoid tissues. Lyon: IARC Press, 2001
2. Meusers P, Hense J, Brittinger G. Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997; 11 Suppl. 2: S60-4
3. Lenz G, Dreyling M, Hiddemann W. Mantle cell lymphoma: established therapeutic options and future directions. Ann Hematol 2004; 83 (2): 71-7
4. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005; 131 (1): 29-38
5. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3 (2): 185-97
6. Fernandez V, Hartmann E, Ott G, et al. Pathogenesis of mantle cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol 2005; 23 (26): 6364-9
7. Witzig TE. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23 (26): 6409-14
8. Cohen PL, Kurtin PJ, Donovan KA, et al. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998; 101 (2): 302-10
9. Romaguera JE, Medeiros LJ, Hagemeister FB, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97 (3): 586-91
10. Oinonen R, Franssila K, Elonen E. Central nervous system involvement in patients with mantle cell lymphoma. Ann Hematol 1999; 78 (3): 145-9
11. Montserrat E, Bosch F, Lopez-Guillermo A, et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996; 14 (3): 941-4
12. Chua SL, Seymour JF, Streater J, et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43 (9): 1783-8
13. Weisenburger DD, Vose JM, Greiner TC, et al. Mantle cell lymphoma: a clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. Am J Hematol 2000; 64 (3): 190-6
14. Khouri IF, Saliba RM, Okoroji GJ, et al. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003; 98 (12): 2630-5
15. Raty R, Franssila K, Joensuu H, et al. Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002; 69 (1): 11-20
16. Pott C, Schrader C, Gesk S, et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006; 107 (6): 2271-8
17. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20 (5): 1288-94
18. Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14 (10): 1555-61
19. M'Kacher R, Bennaceur A, Farace F, et al. Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma. Oncogene 2003; 22 (39): 7905-12
20. Meusers P, Engelhard M, Bartels H, et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989; 7 (5): 365-80
21. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6 (3): 257-62
22. Lenz G, Hiddemann W, Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004; 101 (5): 883-93
23. Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002; 38 (13): 1739-46
24. Zinzani PL, Magagnoli M, Moretti L, et al. Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica 1999; 84 (11): 1002-6
25. Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000; 18 (4): 773-9
26. Seymour JF, Grigg AP, Szer J, et al. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer 2002; 94 (3): 585-93
27. Thomas DW, Owen RG, Johnson SA, et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46 (4): 549-52
28. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104 (10): 3064-71
29. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96 (1): 71-5
30. Cohen BJ, Moskowitz C, Straus D, et al. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma 2001; 42 (5): 1015-22
31. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO#19). J Cancer Res Clin Oncol 2006; 132 (2): 105-12
32. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23 (15): 3383-9
33. Weide R, Heymanns J, Thomalla J, et al. Bendamustine/mitoxantrone/ rituximab (BMR): a very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas: high response rate in patients pretreated with rituximab. Results of a multicentre phase-II-study of the German Low Grade Lymphoma Study Group (GLSG) [abstract no. 6616]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). Proc Annu Meet Am Soc Clin Oncol 2005; 23 (16s): 589s
34. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16 (4): 587-93
35. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16 (12): 3803-9
36. de Guibert S, Jaccard A, Bernard M, et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006; 91 (3): 425-6
37. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23 (28): 7013-23
38. Ketterer N, Salles G, Espinouse D, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8 (7): 701-4
39. Stewart DA, Vose JM, Weisenburger DD, et al. The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6 (3): 263-6
40. Freedman AS, Neuberg D, Gribben JG, et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16 (1): 13-8
41. Haas R, Brittinger G, Meusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10 (12): 1975-9
42. Blay JY, Sebban C, Surbiguet C, et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21 (1): 51-4
43. Kroger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998; 21 (1): 55-7
44. Dreger P, Martin S, Kuse R, et al. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Hematol J 2000; 1 (2): 87-94
45. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105 (7): 2677-84
46. Buske C, Weigert O, Dreyling M, et al. Current status and perspective of antibody therapy in follicular lymphoma. Haematologica 2006; 91 (1): 104-12
47. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23 (4): 705-11
48. Morschhauser F, Leonard J, Coiffier B, et al. Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in non-Hodgkin's lymphoma [abstract]. Blood 2005; 106 (11): 683a
49. Leonard JP, Coleman M, Ketas J, et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005; 23 (22): 5044-51
50. DiJoseph JF, Armellino DC, Boghaert ER, et al. Antibody targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 2004; 103 (5): 1807-14
51. Younes A, Hariharan K, Allen RS, et al. Initial trials of anti-CD80 monoclonal antibody (Galiximab) therapy for patients with relapsed or refractory follicular lymphoma. Clin Lymphoma 2003; 3 (4): 257-9
52. Nagy ZA, Hubner B, Lohning C, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002; 8 (8): 801-7
53. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23 (9): 1984-92
54. Herold M, Dolken G, Fiedler F, et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: chemotherapy versus chemotherapy plus rituximab. Ann Hematol 2003; 82 (2): 77-9
55. Hiddemann W, Forstpointner R, Dreyling M, et al. Rituximab maintenance prolongs response duration after salvage therapy with R-FCM in patients with relapsed follicular lymphomas and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005; 106 (11): 920
56. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108 (13): 4003-8
57. Kahl B, Longo W, Eickhoff J, et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17 (9): 1418-23
58. Schulz H, Bohlius J, Skoetz N, et al. Combined immunochemotherapy with rituximab improves overall survival in patients with follicular and mantle cell lymphoma: updated meta-analysis results. Blood 2006; 106 (11): 106-7a
59. Gianni AM, Magni M, Martelli M, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102 (2): 749-55
60. Mangel J, Leitch HA, Connors JM, et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004; 15 (2): 283-90
61. Thieblemont C, Antal D, Lacotte-Thierry L, et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005; 104 (7): 1434-41
62. European MCL Network [online]. Available from URL: http://www.European- MCL.net [Accessed 2007 May 30]
63. Johansson L, Carlsson J, Nilsson K. Radiosensitivity of human B-lymphocytic lymphomas in vitro. Int J Radiat Biol Relat Stud Phys Chem Med 1982; 41 (4): 411-20
64. Safwat A. The role of low-dose total body irradiation in treatment of non-Hodgkin's lymphoma: a new look at an old method. Radiother Oncol 2000; 56 (1): 1-8
65. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Semin Oncol 2003; 30 (2 Suppl. 4): 10-21
66. Anderson KC, Bates MP, Slaughenhoupt BL, et al. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63 (6): 1424-33
67. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69 (2): 584-91
68. Tedder TF, Boyd AW, Freedman AS, et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985; 135 (2): 973-9
69. Rao AV, Akabani G, Rizzieri DA. Radioimmunotherapy for non-Hodgkin's lymphoma. Clin Med Res 2005; 3 (3): 157-65
70. Younes A, Pro B, Rodriguez MA, et al. Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract no. 2452]. Blood 2005; 106 (11): 689a
71. Weigert O, Schilling C, Rummel MJ, et al. Efficacy and safety of a single-course of yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin®) in patients with relapsed or refractory mantle cell lymphoma (MCL) after/not appropriate for autologous stem cell transplantation (ASCT): a phase II trial of the European MCL Network [abstract no. 4786]. Blood 2005; 106 (11): 277b
72. Zelenetz A, Noy A, Pandit-Taskar N, et al. Sequential radioimmunotherapy with tositumomab/iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions [abstract]. Proc Am Soc Clin Oncol 2006; 24 (18S): 436s
73. Weigert O, Jurczak W, Schilling C, et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG [abstract]. Proc Am Soc Clin Oncol 2006; 24 (18S): 430s
74. Devizzi L, Seregni E, Guidetti A, et al. High-dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has minimal toxicity and full feasibility in an outpatient setting [abstract]. Blood 2005; 106 (11): 768a
75. Shimoni A, Zwas T, Oksman Y, et al. Ibritumomab tiuxetan (Zevalin) in the conditioning regimen for autologous and reduced-intensity allogeneic stem-cell transplantation in patients with chemo-refractory non-Hodgkin's lymphoma [abstract no. 1131]. Blood 2005; 106 (11): 329a
76. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99 (9): 3158-62
77. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63 (23): 8226-32
78. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5 (4): 297-309
79. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21
80. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4 (5): 349-60
81. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348 (26): 2609-17
82. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352 (24): 2487-98
83. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20 (22): 4420-7
84. O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23 (4): 676-84
85. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23 (4): 667-75
86. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24 (13): 2105-12
87. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24 (30): 4867-74
88. Jeremias I, Kupatt C, Baumann B, et al. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91 (12): 4624-31
89. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101 (6): 2377-80
90. Leonard J, Furman R, Cheung Y-K, et al. Phase I/II trial of bortezomib + CHOP-rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): phase I results [abstract]. Blood 2005; 106 (11): 147a
91. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105 (8): 3058-65
92. Weigert O, Pastore A, Rieken M, et al. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007; 21 (3): 524-8
93. Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104 (8): 2269-71
94. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23 (23): 5347-56
95. Ansell SM, Geyer SM, Kurtin P, et al. Anti-tumor activity of mTOR inhibitor temsirolimus for relapsed mantle cell lymphoma: a phase II trial in the North Central Cancer Treatment Group [abstract]. Proc Am Soc Clin Oncol 2006; 24 (18s): 430s
96. Kouroukis CT, Belch A, Crump M, et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21 (9): 1740-5
97. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109 (2): 399-404
98. Kroger N, Hoffknecht M, Kruger W, et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000; 79 (10): 578-80
99. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003; 21 (23): 4407-12
100. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100 (13): 4310-6